Related Experiment Video

Updated: Jan 21, 2026

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.2K

Cecropin A Alleviates Inflammation Through Modulating the Gut Microbiota of C57BL/6 Mice With DSS-Induced IBD

Zhenya Zhai1, Fan Zhang1, Ruihua Cao1

  • 1Guangdong Provincial Key Laboratory of Animal Nutrition Control, National Engineering Research Center for Breeding Swine Industry, College of Animal Science, Subtropical Institute of Animal Nutrition and Feed, South China Agricultural University, Guangzhou, China.

Frontiers in Microbiology
|July 30, 2019
PubMed

Insights

Antimicrobial peptide cecropin A effectively alleviates inflammatory bowel disease (IBD) in mice by reducing harmful gut bacteria and promoting beneficial ones like Lactobacillus. Its therapeutic mechanism differs from the antibiotic gentamicin.

Area of Science:

  • Microbiology
  • Immunology
  • Gastroenterology

Background:

  • Inflammatory bowel disease (IBD) is a chronic condition characterized by gut inflammation.
  • Gut microbiota dysbiosis is implicated in IBD pathogenesis.
  • Antimicrobial peptides (AMPs) like cecropin A are being investigated for therapeutic potential.

Purpose of the Study:

  • To evaluate the therapeutic effects of cecropin A on dextran sulfate sodium (DSS)-induced IBD in C57BL/6 mice.
  • To compare the efficacy and gut microbiota modulation of cecropin A with the antibiotic gentamicin.
  • To elucidate the underlying mechanisms of cecropin A in alleviating IBD.

Main Methods:

  • Establishment of severe and moderate IBD mouse models using DSS.
  • Intraperitoneal administration of varying cecropin A doses to determine safety and efficacy.
  • Assessment of survival rates, body weight, disease activity index (DAI), and colonic cytokine levels (TNF-α, IL-1β, IL-6).
  • Analysis of gut microbiota composition using 16S rRNA gene sequencing.

Main Results:

  • Cecropin A (15 mg/kg) significantly improved survival rates and reduced body weight loss in severe IBD mice.
  • Both cecropin A and gentamicin reduced DAI, gut mucosal damage, and key inflammatory cytokines (TNF-α, IL-1β, IL-6).
  • Cecropin A selectively enriched beneficial *Lactobacillus* species, while gentamicin affected *Desulfovibrionaceae* and *Ruminococcaceae*.
  • Both treatments decreased the abundance of detrimental *Bacteroidaceae* and *Enterobacteriaceae*.

Conclusions:

  • Cecropin A demonstrates significant therapeutic potential for IBD by mitigating inflammation and restoring gut microbiota balance.
  • Cecropin A's mechanism involves reducing pathogenic bacteria and promoting beneficial bacteria, distinct from gentamicin's effects.
  • Cecropin A represents a promising alternative therapeutic agent for IBD management.
Keywords:
C57BL/6 miceantimicrobial peptidegut microbiotainflammatory bowel diseaseintestinal barrier

More Related Videos

A Method to Assess Bacteriocin Effects on the Gut Microbiota of Mice07:54

A Method to Assess Bacteriocin Effects on the Gut Microbiota of Mice

Published on: July 25, 2017

14.7K
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

10.0K

Related Concept Videos

Inflammation01:38

Inflammation

Overview
61.8K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
468
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
443
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
503
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
510
Physiology of Enteric Nervous System and Gut Health01:05

Physiology of Enteric Nervous System and Gut Health

The gastrointestinal tract, responsible for the digestion and absorption of nutrients, is safeguarded by the intestinal barrier, which consists of secretory, physical, and immune components. At the forefront is the secretory barrier, composed of essential elements such as mucus, gut microbiota, and defense proteins. They collaborate to break down food particles, facilitate nutrient absorption, and maintain optimal gut health. These secretory components ensure the smooth functioning of the...
898